National Blood Authority
A report by the National Blood Authority Haemovigilance Advisory Committee


[viii] A nomogram is a chart or graph used to show relationships between several variables (such as height and weight) to enable a third value (collection volume, which is based on the total blood volume) to be read directly at the intersection point of the first two values.

[1] European Union Directive 2002/98/EC setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC. European Union, 2003.

[3] Faber JC. Worldwide overview of existing haemovigilance systems. Transfusion and Apheresis Science 2004; 31: 99-110.

[4] World Health Organization: Global Database on Blood Safety Summary Report 2011.

[5] Berger K, Klein HG, Seitz R, Schramm W, Spieser JM. The Wildbad Kreuth initiative: European current practices and recommendations for optimal use of blood components. Biologicals 2011;39(3):189-93.

[6] ABS-3101.0 Australian Demographic Statistics. Canberra.

[7] ABS-3101.0 Australian Demographic Statistics. Canberra.

[8] Economic Implications of an ageing Australia. Productivity Commission 2005. Canberra.

[10] Limitations of the data. Australian Institute of Health and Welfare.

[11] Cobain TJ, Vamvakis EC, Wells A, Titlestad K. A Survey of the Demographics of Blood Use. Transfusion Medicine 2007; 17(1):1-15.

[12] Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ, van Hout BA. The PROTON study: profiles of blood product transfusion recipients in the Netherlands. Vox Sanguinis 2010; 99(1) 54-64.

[13] Currie CJ, Patel TC, McEwan P, Dixon S. Evaluation of the future supply and demand for blood products in the United Kingdom National Health Service. Transfusion Medicine 2004; 14(1):19-24.

[14] Greinacher A, Fendrich K, Alpen U, Hoffmann W. Impact of demographic changes on the blood supply: Mecklenburg-West Pomerania as a model region for Europe. Transfusion 2007; 47(3):395-401.

[15] Borkent-Raven BA, Janssen MP, and Van Der Poel CL. Demographic changes and predicting blood supply and demand in the Netherlands. Transfusion 2010; 50(11):2455-2460.

[16] Tinegate H, Chattree S, Iqbal A, Plews D, Whitehead J, Wallis JP. Ten-year pattern of red blood cell use in the North of England. Transfusion 2013, 53(3): 483-489.

[18] Shortt J, Polizzotto MN, Waters N, Borosak M, Moran M, Comande M, et al. Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use. Transfusion 2009; 49(11):2296 - 2303.

[19] Proposed standard definitions for surveillance of non-infectious adverse transfusion reactions. ISBT.

[20] Faber JC. Worldwide overview of existing haemovigilance systems. Transfusion and Apheresis Science 2004; 31(2): 99-110.

[22] Blood Matters Program, Department of Health, Victoria, Australia.

[23] Amrein K, Valentin A, Lanzer G, Drexler C. Adverse events and safety issues in blood donation-a comprehensive review. Blood Reviews 2012; 26(1):33-42.

[24] Patient Blood Management Guidelines: Module 2- Perioperative. National Blood Authority.

[25] Miller K, Akers C, Magrin G, Whitehead S, Davis AK. Piloting the use of 2D barcode and patient safety-software in an Australian tertiary hospital setting. Vox Sanguinis 2013;

[26] Eder AF, Dy BA, Kennedy JM, Notari IV EP, Strupp A, Wissel ME, Reddy R, Gibble J, Haimowitz MD, Newman BH, Chambers LA, Hillyer CD, Benjamin RJ. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008; 48: 1809-1819. doi: 10.1111/j.1537-2995.2008.01811.x

[27] Newman, Bruce H, Pichette S, Pichette D, Dzaka E. Adverse effects in blood donors after whole-blood donation: a study of 1000 blood donors interviewed 3 weeks after whole-blood donation. Transfusion 2003; 43: 598-603. doi: 10.1046/j.1537-2995.2003.00368.x

[28] Goldman M, Osmond L, Yi Q-L, Cameron-Choi K, O'Brien SF. Frequency and risk factors for donor reactions in an anonymous blood donor survey. Transfusion 2012: doi: 10.1111/trf.12011

[29] Eder AF. Improving Safety for Young Blood Donors. Transfusion Medicine Reviews 2012:26 (1): 14-26

[30] Calman K. The Health of the Nation. British Journal of Hospital Medicine 1996; 56 pp125-126.

[31] Blood Component Information Circular of Information An extension of blood component labels 2012. Australian Red Cross Blood Service.

[32] Geiger TL, Howard SC. Acetaminophen and diphenhydramine pre-medication for allergic and febrile non haemolytic transfusion reactions: good prophylaxis or bad practice? Transfusion Medicine Review 2007; 21(1):1-12.

[33] Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion 2007; 47(6):1089-1096.

[34] Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT. Pre-storage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 2001; 41 pp997-1000.

[35] R├╝ggeberg JU, Gold MS, Bayas J-M, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25(31):5675-5684.

[36] Johansson SG, Hourihnne JO , Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56(9):813-824.

[37] Johansson SG. Bieber T, Dahl R, Friedmann PS. Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy and Clinical Immunology 2004; 113(5):832-836.

[38] Sampson HA, Munoz-Furlong A, Bock SA , Schmitt C, Buss R, Chowdhury BA, et al. Symposium on the definition and management of anaphylaxis: summary report. Journal of Allergy and Clinical Immunology 2005; 115(3):584-591.

[39] Tinegate H, Birchall J, Gray A, Haggas R, Massey E, Norfolk D, Pinchon D, Sewell C, Wells A, Allard S. Guideline on the investigation and management of acute transfusion reactions. British Journal of Haematology 2012; 159(2):143-153.

[40] Stainsby D, Knowles SM, Milkins C, Jones H, Cohen H. Can haemolytic transfusion reactions be avoided by better transfusion practice? Vox Sanguinis 2005; 89 (Suppl. 1):14.

[41] Milkins C, Knowles S, DeSilva M, Contreras M, Stainsby D. Prevention and diagnosis of delayed haemolytic transfusion reactions. Vox Sanguinis 2006; 91(4):365-367.

[42] Serious Hazards of Transfusion (SHOT) Annual Report 2011. SHOT, National Blood Service, National Health Service, UK.

[43] Hannema SE, Brand A, van Meurs A, Smiers F J. Delayed hemolytic transfusion reaction with hyperhemolysis after first red blood cell transfusion in child with -thalassemia: challenges in treatment. Transfusion 2010; 50(2): 429-432.

[44] Zhou L, Giacherio D, Cooling L, et al. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion 2005; 45(7): 1056-1063.

[45] Popovsky MA. Transfusion-associated circulatory overload. ISBT Science Series 2008; 3(1) pp166-169.

[46] Webert KE, Blajchman MA. Transfusion-related acute lung injury. Current Opinion in Hematology 2005; 12 pp480-487.

[47] Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25(6):573-577.

[48] Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004; 44(12):1774-1789.

[49] Roback JD et al. Non-infectious complications of blood transfusion. Chapter 2, AABB Technical Manual. 17th Edition. AABB, Bethesda. 2011

[50] Fatalities Reported to the FDA Following Blood Collection and Transfusion, Annual Summary for Fiscal Year 2011, 2012. Food and Drug Administration, US.

[51] Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, Navarrete C, Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM; Serious Hazards of Transfusion Steering Group (2009). Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 49(3): 440-452.

[52] Dagger J, Dinesh D et al. National Haemovigilance Program Annual Report 2011. New Zealand Blood Service, NZ.

[53] Wagner SJ. Transfusion-Transmitted Bacterial Infection: Risks, Sources and Interventions. Vox Sanguinis 2004; 88(1):60.

[54] Dzik WH. New technology for transfusion safety. British Journal of Haematology 2007; 136(2):181-190.

[55] Ohsaka A, Abe K, Ohsawa T, Miyake N, Sugita S, Tojima I. A computer-assisted transfusion management system and changed transfusion practices contribute to appropriate management of blood components. Transfusion 2008; 48(8):1730-1738.

[57] Serious transfusion incident report 2009-11. Blood Matters, Department of Health, Victoria.

[58] Noel L, Debeir J, Cosson A. The French haemovigilance system. Vox Sanguinis 1998; 74(S2):441-445.

[60] de Vries RR, Faber JC, Strengers PF. Haemovigilance: an effective tool for improving transfusion practice. Vox Sanguinis 2011; 100(1):60-67.

[61] 15th International Haemovigilance Seminar. International Haemovigilance Network.

[62] Global Database on Blood Safety Summary Report 2011. Word Health Organization.

[63] Global Consultation on Haemovigilance. Word Health Organization.

Back to Top